<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002554</url>
  </required_header>
  <id_info>
    <org_study_id>832.00</org_study_id>
    <secondary_id>CDR0000063421</secondary_id>
    <secondary_id>NCI-V94-0393</secondary_id>
    <nct_id>NCT00002554</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse</brief_title>
  <official_title>RADIOLABELED BC8 (ANTI-CD45) ANTIBODY COMBINED WITH BUSULFAN AND CYCLOPHOSPHAMIDE AS TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA IN FIRST OR SECOND REMISSION OR UNTREATED FIRST RELAPSE FOLLOWED BY HLA-IDENTICAL RELATED MARROW TRANSPLANTATION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver&#xD;
      cancer-killing substances to them without harming normal cells. Monoclonal antibody combined&#xD;
      with a radioactive substance and given prior to bone marrow transplantation may kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of radiolabeled monoclonal antibody given&#xD;
      prior to bone marrow transplantation in treating patients with acute myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the overall and disease-free survival and toxicity associated with&#xD;
      busulfan/cyclophosphamide (BU/CTX) plus 131I-labeled BC8 antibody (131I-BC8) followed by an&#xD;
      HLA-identical related marrow transplant in patients with acute myelogenous leukemia in first&#xD;
      or second remission or untreated first relapse. II. Study factors that may influence the&#xD;
      biodistribution of 131I-BC8 in this patient population, including marrow cellularity, the&#xD;
      level of antigen expression by leukemic cells (in relapsed patients), and the degree of&#xD;
      antigen saturation by antibody. III. Determine the efficacy of BU/CTX in patients in first&#xD;
      remission unable to receive radiolabeled antibody, e.g., patients who are HAMA-positive,&#xD;
      those not tolerating antibody test infusion, those with unfavorable antibody biodistribution,&#xD;
      or those for whom antibody is unavailable.&#xD;
&#xD;
      OUTLINE: Radioimmunotherapy plus 2-Drug Cytoreductive Chemotherapy followed by Bone Marrow&#xD;
      Transplantation with, as indicated, CNS Therapy. Iodine-131-labeled Monoclonal Antibody BC8&#xD;
      (anti-CD45), 131I-BC8; plus Busulfan, BU, NSC-750; Cyclophosphamide, CTX, NSC-26271; followed&#xD;
      by Allogeneic Bone Marrow, ABM; with, as indicated, Intrathecal Methotrexate, IT MTX,&#xD;
      NSC-740.&#xD;
&#xD;
      PROJECTED ACCRUAL: It is anticipated that 30 patients in first remission, 30 patients in&#xD;
      untreated first relapse, and 15 patients in second remission will be accrued over 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1993</start_date>
  <completion_date type="Actual">December 1999</completion_date>
  <primary_completion_date type="Actual">December 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radioimmunotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute myelogenous leukemia in first or second remission or&#xD;
        untreated first relapse Documented CD45 expression by leukemic cells required for patients&#xD;
        in relapse Phenotyping not required for patients in remission; such patients may have&#xD;
        leukemia previously documented to be CD45 negative Circulating blast count less than 10,000&#xD;
        (control with hydroxyurea or similar agent allowed) Genotypically or phenotypically&#xD;
        HLA-matched related marrow donor required No donors mismatched for 1 or more HLA antigens&#xD;
        No psychologic, physiologic, or medical contraindication to donation No high risk for&#xD;
        anesthesia because of age or medical problems No HIV seropositive donors&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 to 55 Performance status: Not specified Life expectancy:&#xD;
        Greater than 60 days Hematopoietic: Not applicable Hepatic: Bilirubin less than 1.5 mg/dl&#xD;
        No risk of developing veno-occlusive disease of the liver (i.e., current evidence of&#xD;
        hepatitis as manifested by SGOT greater than 1.5 x ULN) Renal: Creatinine less than 2.0&#xD;
        mg/dl Other: No HIV seropositivity No major infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: See Disease Characteristics No prior radiotherapy to maximally&#xD;
        tolerated levels for any normal organ&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pagel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2004</study_first_posted>
  <last_update_submitted>March 29, 2010</last_update_submitted>
  <last_update_submitted_qc>March 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2010</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

